Artiva Ends Autoimmune Cell Therapy Program After Two Patient Deaths and Disappointing Long-Term Results
Artiva Ends Autoimmune Cell Therapy Program After Two Patient Deaths and Disappointing Long-Term Results
Author
Artiva Ends Autoimmune Cell Therapy Program After Two Patient Deaths and Disappointing Long-Term Results
There is no routine screening test for the general population. There is a conversation for people at higher risk. Who starts it?
A referral is not an appointment. An authorization is not a payment guarantee. A clinical recommendation begins a process; the people and institutions controlling that process deserve public scrutiny.
A 2025 Maryland study found Black decedents were far more likely to be classified 'undetermined' than white decedents. MB is asking whether New York has the same gap.
OFFICIAL LAUNCH ARTICLE | Melanin Bliss Media introduces a foundational reporting series on the systems between needing healthcare and receiving it.
New economic numbers, the final days of early voting, and the healthcare paperwork that deserves a closer look.
Your hospital's has a document that names, in writing, what that hospital has decided your community needs most what it promised to do about it.
Black Death Doulas Aren’t Inventing Care at the End of Life. They’re Carrying an Older Obligation Forward.
Early voting is underway, household budgets remain under pressure, and MB’s foundational new series, The Back Office of Care, launches Friday.
Thursday, October 8, 2026 Coverage window: Friday, October 2–Thursday, October 8 Sometimes the headline says things are steady while our lives
what to ask before an insurer says “wait,” and where to turn if money is part of the harm.
The share of men starting breast cancer treatment within 30 days of diagnosis fell from 76% to 36% in under two decades, according to new American Cancer Society research. Coverage was a major dividing line.